1 / 7

Tyvaso ( treprostinil )

Tyvaso ( treprostinil ). By: Alaa Tuffaha Pharm D. About Tyvaso. Company: united therapeutics Approval date: Approved July 2009 Treatment Area: pulmonary arterial hypertension

jace
Download Presentation

Tyvaso ( treprostinil )

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Tyvaso (treprostinil) By: AlaaTuffaha Pharm D

  2. About Tyvaso Company: united therapeutics Approval date: Approved July 2009 Treatment Area: pulmonary arterial hypertension Tyvaso is specifically indicated to increase walk distance in patients with WHO Group I pulmonary arterial hypertension.

  3. Pulmonary Arterial Hypertension pulmonary arterial hypertension (WHO Group I) involves the vasoconstriction or tightening of blood vessels in the lungs this makes it harder for the heart to pump blood causing hypertrophy of the right ventricle ultimately causing right heart failure. Symptoms: Shortness of breath (dyspnea) especially during exercise ,dizziness, swelling (edema), chest pain.

  4. MOA Tyvaso is a prostacyclin analogue. • It directs vasodilation of pulmonary and systemic arterial vascular beds • and inhibits platelet aggregation.

  5. Side Effects Adverse events associated with the use of Tyvaso may include, but are not limited to, the following: Cough Headache Throat Irritation Nausea Flushing Syncope

  6. Dosage Route of administration: oral inhalation. Frequency: 4 times a day during waking hours spaced 4 hours apart Initial Dosage:Therapy should begin with 3 breaths of Tyvaso per treatment session(18 mcg of treprostinil), 4 times daily. If 3 breaths are not tolerated, reduce to 1 or 2 breaths and subsequently increase to 3 breaths, as tolerated.Maintenance Dosage:Dosage should be increased by an additional 3 breaths at approximately 1-2 week intervals, if tolerated, until the target dose of 9 breaths (54 mcg of treprostinil) is reached per treatment session, 4 times daily. Tyvaso should be continued at the highest tolerated dose. The maximum recommended dosage is 9 breaths per treatment session, 4 times daily.

  7. references • www.centerwatch .com • www.tyvaso.com • www.wikipedia.com • http://ghr.nlm.nih.gov

More Related